Trastuzumab deruxtecan for HER2-positive metastatic GI cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called trastuzumab deruxtecan for people with advanced HER2-positive cancer of the esophagus, stomach, or gastroesophageal junction who haven't had prior systemic treatment for metastatic disease. The drug may help shrink tumors by targeting the HER2 protein and delivering chemotherapy directly to cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer of the esophagus, stomach, or the area where they meet (gastroesophageal junction) that can't be removed with surgery and has spread.
- Your tumor must be HER2-positive, meaning it has a specific protein or gene change that the study drug targets.
- You have not had prior systemic treatment for metastatic disease, though you may have had radiation or surgery to help with symptoms.
- You are able to perform daily activities with some help (ECOG performance status of 2 or better).
- Your heart and lungs must be healthy enough, with no significant lung disease or recent heart problems.
- You are willing to use effective contraception if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
This trial tests a drug called trastuzumab deruxtecan (an antibody-drug conjugate) in people with advanced non-small cell lung cancer that has high levels of HER2. The drug is designed to target and kill cancer cells while sparing healthy cells, and the study will see how well it works and how safe it is.
This trial tests if trastuzumab deruxtecan, a targeted drug, can help people with HER2-positive stomach or gastroesophageal junction cancer who still have cancer cells detected after surgery and chemotherapy. It aims to prevent the cancer from coming back.
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
This trial tests a combination of two drugs (trastuzumab deruxtecan and an immunotherapy) given before surgery to shrink early-stage breast cancer tumors. It is for people whose tumors have low levels of HER2 and are hormone receptor positive.
Hear when a new HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.